Literature DB >> 6979708

Preoperative prediction of reversible myocardial asynergy by postexercise radionuclide ventriculography.

A Rozanski, D Berman, R Gray, G Diamond, M Raymond, J Prause, J Maddahi, H J Swan, J Matloff.   

Abstract

Myocardial asynergy is sometimes reversed by coronary bypass, and a noninvasive method of predicting which assess are reversible would be desirable. To assess whether changes in myocardial wall motion observed immediately after exercise can differentiate reversible from nonreversible myocardial asynergy, we evaluated 53 patients by radionuclide ventriculography before and after exercise and again at rest after coronary bypass surgery. Preoperative improvement in wall motion immediately after exercise was highly predictive of the surgical outcome (average chance-corrected agreement, 91 per cent). At surgery the asynergic segments that had improved after exercise were free of grossly apparent epicardial scarring. The accuracy of these predictions for postoperative improvement was significantly greater (P less than 0.01) than that of analysis of Q waves on resting electrocardiography (average chance-corrected agreement, 40 per cent). In contrast, preoperative changes in left ventricular ejection fraction after exercise were not predictive of postoperative resting ejection fraction. We conclude that postexercise radionuclide ventriculography can be used to identify reversible resting myocardial asynergy. This test should prove effective in predicting which patients with myocardial asynergy are most likely to benefit from aortocoronary revascularization.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6979708     DOI: 10.1056/NEJM198207223070402

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  21 in total

Review 1.  The historical and conceptual evolution of radionuclide assessment of myocardial viability.

Authors:  James E Udelson; Robert O Bonow; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2004 May-Jun       Impact factor: 5.952

2.  Assessment of Regional Viability in the Infarct Zone Following Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 3.  Hibernation and myocardial ischemia: clinical detection by positron emission tomography.

Authors:  N G Uren; P G Camici
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

4.  Proceed with caution: reliance on coronary angiography to exclude organic disease in women.

Authors:  Alan Rozanski
Journal:  J Nucl Cardiol       Date:  2006-07       Impact factor: 5.952

5.  Comparison of post-stress ejection fraction and relative left ventricular volumes by automatic analysis of gated myocardial perfusion single-photon emission computed tomography acquired in the supine and prone positions.

Authors:  D Berman; G Germano; H Lewin; X Kang; P B Kavanagh; P Tapnio; M Harris; J Friedman
Journal:  J Nucl Cardiol       Date:  1998 Jan-Feb       Impact factor: 5.952

6.  Clinical application of radionuclide angiography.

Authors:  S C Port; F J Wackers
Journal:  J Nucl Cardiol       Date:  1995 Nov-Dec       Impact factor: 5.952

7.  Tomographic radionuclide ventriculography: opportunity ignored?

Authors:  J R Corbett
Journal:  J Nucl Cardiol       Date:  1994 Nov-Dec       Impact factor: 5.952

8.  Should early post-stress imaging be performed on a routine clinical basis for myocardial perfusion studies?

Authors:  Raymond Taillefer
Journal:  J Nucl Cardiol       Date:  2014-09-12       Impact factor: 5.952

Review 9.  Assessment of viability after myocardial infarction. Clinical relevance and methodological problems.

Authors:  G Fragasso; A Margonato; S L Chierchia
Journal:  Int J Card Imaging       Date:  1993

10.  Stress-related variations in left ventricular function as assessed with gated myocardial perfusion SPECT.

Authors:  Hein J Verberne; Marcel G W Dijkgraaf; G Aernout Somsen; Berthe L F van Eck-Smit
Journal:  J Nucl Cardiol       Date:  2003 Sep-Oct       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.